Cara Current Deferred Revenue vs Ebit Per Revenue Analysis

CARA Stock

USD 0.30 0.01 3.45%

Cara Therapeutic financial indicator trend analysis is way more than just evaluating Cara Therapeutic prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cara Therapeutic is a good investment. Please check the relationship between Cara Therapeutic Current Deferred Revenue and its Ebit Per Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

Current Deferred Revenue vs Ebit Per Revenue

Current Deferred Revenue vs Ebit Per Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cara Therapeutic Current Deferred Revenue account and Ebit Per Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Cara Therapeutic's Current Deferred Revenue and Ebit Per Revenue is -0.25. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Ebit Per Revenue in the same time period over historical financial statements of Cara Therapeutic, assuming nothing else is changed. The correlation between historical values of Cara Therapeutic's Current Deferred Revenue and Ebit Per Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Cara Therapeutic are associated (or correlated) with its Ebit Per Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit Per Revenue has no effect on the direction of Current Deferred Revenue i.e., Cara Therapeutic's Current Deferred Revenue and Ebit Per Revenue go up and down completely randomly.

Correlation Coefficient

-0.25

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Ebit Per Revenue

Most indicators from Cara Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cara Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.Tax Provision is expected to grow at the current pace this year, whereas Selling General Administrative is forecasted to decline to about 15.7 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	112.1M	122.1M	136.3M	77.9M
Cost Of Revenue	1.6M	7.3M	6.2M	5.9M

Total Operating Expenses Cost Of Revenue

Cara Therapeutic fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		0.12	0.74	0.75	0.98	0.81	0.01	-0.28	-0.69	0.6	0.34	0.83	-0.22	-0.57	0.98	0.54	0.87	0.86	0.94	0.19	0.7	0.89	0.5	0.02	0.98	0.59
Short Long Term Debt Total	0.12		0.68	0.23	0.0	0.54	0.75	0.16	-0.69	0.72	0.58	-0.12	0.22	-0.69	0.14	0.69	0.37	0.38	0.08	0.95	0.21	0.36	0.79	0.82	0.16	0.5
Other Current Liab	0.74	0.68		0.75	0.63	0.92	0.44	-0.12	-0.95	0.95	0.6	0.44	-0.16	-0.87	0.75	0.89	0.84	0.85	0.68	0.75	0.71	0.86	0.88	0.5	0.77	0.71
Total Current Liabilities	0.75	0.23	0.75		0.62	0.8	0.03	-0.13	-0.65	0.68	0.28	0.54	-0.18	-0.61	0.76	0.58	0.72	0.7	0.73	0.39	0.66	0.74	0.76	0.06	0.77	0.34
Total Stockholder Equity	0.98	0.0	0.63	0.62		0.71	-0.06	-0.31	-0.6	0.49	0.29	0.85	-0.25	-0.46	0.95	0.45	0.79	0.79	0.93	0.05	0.64	0.81	0.35	-0.06	0.94	0.53
Other Liab	0.81	0.54	0.92	0.8	0.71		0.44	-0.16	-0.92	0.85	0.56	0.6	-0.24	-0.9	0.78	0.83	0.82	0.83	0.72	0.66	0.74	0.88	0.84	0.47	0.81	0.74
Property Plant And Equipment Net	0.01	0.75	0.44	0.03	-0.06	0.44		0.33	-0.49	0.47	0.31	0.11	0.26	-0.53	-0.09	0.44	0.09	0.11	-0.1	0.68	0.14	0.18	0.51	0.99	-0.06	0.44
Net Debt	-0.28	0.16	-0.12	-0.13	-0.31	-0.16	0.33		0.19	-0.14	-0.71	-0.03	0.72	0.29	-0.33	-0.34	-0.35	-0.38	-0.08	0.08	-0.53	-0.3	0.07	0.32	-0.36	-0.31
Retained Earnings	-0.69	-0.69	-0.95	-0.65	-0.6	-0.92	-0.49	0.19		-0.95	-0.68	-0.4	0.29	0.94	-0.69	-0.94	-0.85	-0.87	-0.59	-0.76	-0.72	-0.89	-0.81	-0.54	-0.73	-0.85
Accounts Payable	0.6	0.72	0.95	0.68	0.49	0.85	0.47	-0.14	-0.95		0.66	0.29	-0.27	-0.89	0.61	0.94	0.78	0.8	0.52	0.77	0.71	0.81	0.85	0.53	0.65	0.7
Cash	0.34	0.58	0.6	0.28	0.29	0.56	0.31	-0.71	-0.68	0.66		-0.01	-0.47	-0.76	0.38	0.79	0.57	0.59	0.13	0.62	0.63	0.53	0.5	0.37	0.42	0.66
Non Current Assets Total	0.83	-0.12	0.44	0.54	0.85	0.6	0.11	-0.03	-0.4	0.29	-0.01		0.02	-0.26	0.71	0.17	0.57	0.57	0.75	-0.12	0.45	0.64	0.22	0.06	0.7	0.39
Non Currrent Assets Other	-0.22	0.22	-0.16	-0.18	-0.25	-0.24	0.26	0.72	0.29	-0.27	-0.47	0.02		0.42	-0.26	-0.47	-0.3	-0.36	-0.09	0.04	-0.66	-0.37	0.06	0.25	-0.31	-0.4
Other Assets	-0.57	-0.69	-0.87	-0.61	-0.46	-0.9	-0.53	0.29	0.94	-0.89	-0.76	-0.26	0.42		-0.57	-0.96	-0.71	-0.75	-0.43	-0.81	-0.76	-0.78	-0.81	-0.58	-0.61	-0.81
Cash And Short Term Investments	0.98	0.14	0.75	0.76	0.95	0.78	-0.09	-0.33	-0.69	0.61	0.38	0.71	-0.26	-0.57		0.57	0.9	0.87	0.95	0.23	0.69	0.88	0.53	-0.06	1.0	0.56
Net Receivables	0.54	0.69	0.89	0.58	0.45	0.83	0.44	-0.34	-0.94	0.94	0.79	0.17	-0.47	-0.96	0.57		0.74	0.77	0.43	0.79	0.8	0.78	0.78	0.51	0.62	0.78
Common Stock Total Equity	0.87	0.37	0.84	0.72	0.79	0.82	0.09	-0.35	-0.85	0.78	0.57	0.57	-0.3	-0.71	0.9	0.74		0.97	0.77	0.43	0.74	0.97	0.62	0.15	0.91	0.78
Common Stock Shares Outstanding	0.86	0.38	0.85	0.7	0.79	0.83	0.11	-0.38	-0.87	0.8	0.59	0.57	-0.36	-0.75	0.87	0.77	0.97		0.74	0.44	0.78	0.97	0.61	0.16	0.89	0.82
Short Term Investments	0.94	0.08	0.68	0.73	0.93	0.72	-0.1	-0.08	-0.59	0.52	0.13	0.75	-0.09	-0.43	0.95	0.43	0.77	0.74		0.16	0.53	0.77	0.49	-0.08	0.94	0.4
Non Current Liabilities Total	0.19	0.95	0.75	0.39	0.05	0.66	0.68	0.08	-0.76	0.77	0.62	-0.12	0.04	-0.81	0.23	0.79	0.43	0.44	0.16		0.34	0.44	0.88	0.76	0.26	0.54
Other Current Assets	0.7	0.21	0.71	0.66	0.64	0.74	0.14	-0.53	-0.72	0.71	0.63	0.45	-0.66	-0.76	0.69	0.8	0.74	0.78	0.53	0.34		0.8	0.49	0.16	0.74	0.69
Other Stockholder Equity	0.89	0.36	0.86	0.74	0.81	0.88	0.18	-0.3	-0.89	0.81	0.53	0.64	-0.37	-0.78	0.88	0.78	0.97	0.97	0.77	0.44	0.8		0.62	0.22	0.91	0.83
Total Liab	0.5	0.79	0.88	0.76	0.35	0.84	0.51	0.07	-0.81	0.85	0.5	0.22	0.06	-0.81	0.53	0.78	0.62	0.61	0.49	0.88	0.49	0.62		0.58	0.54	0.48
Property Plant And Equipment Gross	0.02	0.82	0.5	0.06	-0.06	0.47	0.99	0.32	-0.54	0.53	0.37	0.06	0.25	-0.58	-0.06	0.51	0.15	0.16	-0.08	0.76	0.16	0.22	0.58		-0.03	0.47
Total Current Assets	0.98	0.16	0.77	0.77	0.94	0.81	-0.06	-0.36	-0.73	0.65	0.42	0.7	-0.31	-0.61	1.0	0.62	0.91	0.89	0.94	0.26	0.74	0.91	0.54	-0.03		0.61
Short Term Debt	0.59	0.5	0.71	0.34	0.53	0.74	0.44	-0.31	-0.85	0.7	0.66	0.39	-0.4	-0.81	0.56	0.78	0.78	0.82	0.4	0.54	0.69	0.83	0.48	0.47	0.61

Click cells to compare fundamentals

Cara Therapeutic Account Relationship Matchups

Cara Therapeutic fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	233.0M	271.2M	247.1M	182.2M	125.8M	136.4M
Other Current Liab	10.6M	10.4M	8.5M	10.0M	14.0M	14.7M
Total Current Liabilities	42.9M	18.5M	17.6M	23.5M	25.6M	17.5M
Total Stockholder Equity	186.7M	249.0M	227.5M	158.8M	57.1M	112.3M
Property Plant And Equipment Net	3.7M	5.1M	3.6M	2.0M	8.2M	8.6M
Net Debt	(14.0M)	(26.4M)	(9.8M)	(61.8M)	(8.6M)	(9.0M)
Retained Earnings	(400.7M)	(392.3M)	(480.8M)	(566.2M)	(684.7M)	(650.5M)
Accounts Payable	9.1M	4.9M	5.6M	9.6M	11.6M	12.2M
Cash	18.3M	31.7M	13.5M	63.7M	51.8M	54.4M
Non Current Assets Total	67.3M	76.1M	73.8M	13.3M	9.7M	9.2M
Cash And Short Term Investments	155.0M	180.9M	167.0M	145.4M	100.8M	104.8M
Net Receivables	1.8M	2.1M	1.2M	4.5M	4.0M	4.2M
Common Stock Total Equity	39K	47K	50K	53K	61.0K	33.2K
Common Stock Shares Outstanding	42.7M	47.9M	50.7M	53.7M	54.1M	35.8M
Short Term Investments	136.7M	149.2M	153.6M	81.7M	49.0M	93.8M
Liabilities And Stockholders Equity	233.0M	271.2M	247.1M	182.2M	125.8M	136.4M
Non Current Liabilities Total	3.4M	3.7M	1.9M	11.5M	43.2M	45.3M
Other Current Assets	9.7M	12.1M	2.5M	16.7M	8.6M	5.3M
Other Stockholder Equity	587.2M	641.2M	708.6M	726.6M	742.0M	395.3M
Total Liab	46.2M	22.2M	19.5M	23.5M	68.8M	72.2M
Property Plant And Equipment Gross	3.7M	5.1M	3.6M	2.0M	9.9M	10.3M
Total Current Assets	165.7M	195.1M	173.3M	168.9M	116.2M	112.2M
Accumulated Other Comprehensive Income	170K	73K	(358K)	(1.7M)	(260K)	(273K)
Common Stock	39K	47K	50K	53K	54K	35.2K
Property Plant Equipment	700K	840K	631K	426K	383.4K	364.2K
Net Tangible Assets	190.1M	252.7M	229.4M	158.8M	182.6M	155.7M
Retained Earnings Total Equity	(400.7M)	(392.3M)	(480.8M)	(566.2M)	(509.6M)	(484.1M)
Capital Surpluse	587.2M	641.2M	708.6M	726.6M	835.6M	525.5M
Net Invested Capital	186.7M	249.0M	227.5M	158.8M	57.1M	54.2M
Net Working Capital	122.8M	176.6M	155.7M	145.5M	90.6M	142.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Cara Therapeutic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cara Therapeutic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cara Therapeutic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cara Therapeutic Stock:

How To Invest In Cara

Details

Is Cara Stock a good investment?

Details

What is Cara Therapeutic's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.75)

Revenue Per Share

0.202

Quarterly Revenue Growth

(0.86)

Return On Assets

(0.63)

Return On Equity

(1.84)

The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cara Current Deferred Revenue vs Ebit Per Revenue Analysis

Current Deferred Revenue vs Ebit Per Revenue

Current Deferred Revenue vs Ebit Per Revenue Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Ebit Per Revenue

Cara Therapeutic fundamental ratios Correlations

Cara Therapeutic Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cara Therapeutic fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Assets
Common Stock Shares Outstanding	+ 0.97	Common Stock Total Equity

Net Receivables	- 0.96	Other Assets
Accounts Payable	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Other Current Liab
Net Receivables	- 0.94	Retained Earnings
Retained Earnings	- 0.92	Other Liab
Other Assets	- 0.9	Other Liab